% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hoeltgen:275358,
author = {L. Hoeltgen and E. Meixner and P. Hoegen$^*$ and E.
Sandrini and F. Weykamp$^*$ and T. Forster and M. Vinsensia
and K. Lang and L. König and N. Arians and C. Fremd and L.
L. Michel and K. Smetanay and A. Schneeweiss and M.
Wallwiener and J. Debus$^*$ and J. Hörner-Rieber$^*$},
title = {{P}alliative {R}adiotherapy for {S}ymptomatic {L}ocally
{A}dvanced {B}reast {C}ancer.},
journal = {Technology in cancer research $\&$ treatment},
volume = {22},
issn = {1533-0346},
address = {Thousand Oaks, CA},
publisher = {Sage Publishing},
reportid = {DKFZ-2023-00727},
pages = {153303382311645 -},
year = {2023},
note = {#LA:E050#},
abstract = {Objective: Women with locally advanced breast cancer (LABC)
or inoperable local recurrence often suffer from a
significantly reduced quality of life (QOL) due to local
tumor-associated pain, bleeding, exulceration, or malodorous
discharge. We aimed to further investigate the benefit of
radiotherapy (RT) for symptom relief while weighing the
side-effects. Materials and methods: Patients who received
symptom-oriented RT for palliative therapy of their LABC or
local recurrence in the Department of Radiation Oncology at
Heidelberg University Hospital between 2012 and 2021 were
recorded. Clinical, pathological, and therapeutic data were
collected and the oncological and symptomatic responses as
well as therapy-associated toxicities were analyzed.
Results: We retrospectively identified 26 consecutive women
who received palliative RT with a median total dose of 39 Gy
or single dose of 3 Gy in 13 fractions due to (impending)
exulceration, pain, local hemorrhage, and/or vascular or
plexus compression. With a median follow-up of 6.5 months
after initiation of RT, overall survival at 6 and 12 months
was $60.0\%$ and $31.7\%,$ and local control was $75.0\%$
and $47.6\%,$ respectively. Radiation had to be discontinued
in 4 patients due to oncological clinical deterioration or
death. When completed as initially planned, symptom
improvement was achieved in $95\%$ and WHO level reduction
of analgesics in $28.6\%$ of patients. In $36\%$ $(16\%)$ of
patients, local RT had already been indicated >3 months (>6
months) before the actual start of RT, but was delayed or
not initiated among others in favor of drug alternatives or
systemic therapies. RT-associated toxicities included only
low-grade side-effects (CTCAE I°-II°) with predominantly
skin erythema and fatigue even in the context of re-RT.
Conclusion: Palliative RT in symptomatic LABC or
locoregional recurrence is an effective treatment option for
controlling local symptoms with only mild toxicity. It may
thus improve QOL and should be considered early in
palliative patient care management.},
keywords = {LABC (Other) / exulceration (Other) / hemorrhage (Other) /
pain (Other) / palliative care (Other) / radiation therapy
(Other)},
cin = {E050 / HD01},
ddc = {610},
cid = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37038619},
doi = {10.1177/15330338231164537},
url = {https://inrepo02.dkfz.de/record/275358},
}